Description

Proteins can exist as multiple proteoforms in vivo, as a result of alternative splicing and single-nucleotide polymorphisms (SNPs), as well as posttranslational processing. To address their clinical significance in a

Proteins can exist as multiple proteoforms in vivo, as a result of alternative splicing and single-nucleotide polymorphisms (SNPs), as well as posttranslational processing. To address their clinical significance in a context of diagnostic information, proteoforms require a more in-depth analysis. Mass spectrometric immunoassays (MSIA) have been devised for studying structural diversity in human proteins. MSIA enables protein profiling in a simple and high-throughput manner, by combining the selectivity of targeted immunoassays, with the specificity of mass spectrometric detection.

Reuse Permissions
  • application/pdf

    Download count: 0

    Details

    Contributors
    Date Created
    • 2016-03-17
    Resource Type
  • Text
  • Collections this item is in
    Identifier
    • Digital object identifier: 10.3390/proteomes4010013
    • Identifier Type
      International standard serial number
      Identifier Value
      2227-7382

    Citation and reuse

    Cite this item

    This is a suggested citation. Consult the appropriate style guide for specific citation guidelines.

    Trenchevska, O., Nelson, R., & Nedelkov, D. (2016). Mass Spectrometric Immunoassays in Characterization of Clinically Significant Proteoforms. Proteomes, 4(1), 13. doi:10.3390/proteomes4010013

    Machine-readable links